Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
Daniel J GeorgeKrishnan RamaswamyAhong HuangDavid RussellJack MardekianNeil M SchultzNora JanjanStephen J FreedlandPublished in: Prostate cancer and prostatic diseases (2021)
In the VHA, black men with chemotherapy-naïve mCRPC initiating NHT may have better outcomes than similarly treated white men.